Henderson L W
Rush Medical College, McGaw Park, IL 60085, USA.
Am J Kidney Dis. 1996 Dec;28(6):951-7. doi: 10.1016/s0272-6386(96)90400-x.
Dialysis has moved from a halfway technology to a full contributor to the therapeutic armamentarium of the nephrologist who treats end-stage renal failure. The scientific future for this therapy is bright and limited only by cost pressure in the changing health care environment of today in North America. For the awesome potential of tomorrow's science to arrive at the bedside, there will have to be a collaborative interaction between industry, the nephrologist researcher, and third-party payers, both private and federal. This consortium must direct therapeutic innovation to ensure that new products serve quality as well as quantity of life, so that society's investment in this new science will show a satisfactory return in reduced hospitalization costs and increased patient productivity. The innovations described were selected to meet this "pharmacoeconomic" requirement.
透析已从一项不完善的技术发展成为治疗终末期肾衰竭的肾脏病医生治疗手段的重要组成部分。这种疗法的科学前景光明，仅受当今北美不断变化的医疗保健环境中的成本压力限制。为了让未来令人惊叹的科学潜力应用于临床，行业、肾脏病学研究人员以及私人和联邦第三方支付者之间必须进行合作互动。这个联盟必须引导治疗创新，以确保新产品既能提高生活质量又能延长寿命，从而使社会在这项新科学上的投资能在降低住院成本和提高患者生产力方面获得令人满意的回报。所描述的创新是为满足这一“药物经济学”要求而挑选的。
